Our sole focus is ophthalmology. Our technology is extraordinary.

Ellex has played an important role in the fight against blindness for over two decades, and this leadership is reflected by our status as the fastest growing company in our market. We engineered our first high-performance ophthalmic laser in 1985 and built our business as an original equipment manufacturer (OEM) supplier for established ophthalmic companies. During that time, more than 12,000 ophthalmic laser systems were manufactured for use worldwide.

With the decision in 2005 to sell our laser systems directly to ophthalmologists under the Ellex brand, we made a bold move to transform our business. In 2006, we further expanded our market by acquiring ophthalmic ultrasound technology and products. Today, more than 90 percent of Ellex sales are direct, establishing a platform for growth in years to come.

At Ellex, our clear vision for the future is also demonstrated by our ongoing commitment of approximately 10 percent of annual revenue for research and development. This level of investment, which is at the high end of the range for companies in our industry, is currently funding research into potential new therapies to treat the leading causes of blindness. Ellex also regularly applies for and receives international patents for device and method innovations.

Products

Ellex manufactures and sells its own complete line of photodisruptors, photocoagulators, SLT systems and ultrasound systems for diagnosing and treating cataract, retina and glaucoma conditions.

• A cataract is a clouding of the normally clear lens of the eye that results in a progressive blurring and dimming of vision. Because cataracts usually develop with age, increasing life spans have made cataract surgery the most commonly performed surgical procedure in the world today. Unfortunately, a significant number of cataract surgery patients develop a complication known as a secondary cataract, where scar tissue develops on a normally clear membrane inside the eye and causes a second blurring and dimming of vision.
  
  Photodisruption – Ophthalmologists perform a surgical procedure called laser capsulotomy to treat secondary cataracts – and more ophthalmologists use Ellex photodisruptors to perform this treatment than any other laser brand.  We are the world’s largest Nd: YAG photodisruptor manufacturer, supplying over half of the global market with the Ultra Q and Super Q models.

• The retina’s photoreceptors see light and process the signals that transmit images to the brain. In age-related macular degeneration (AMD) and diabetic retinal diseases, inflammation, abnormal blood vessel growth and atrophy often combine to interfere with healthy retina function. These diseases have become the fastest-growing causes of blindness in the world.
  
  Photocoagulation –  Ellex green and multi-color photocoagulators are unparalleled for treating AMD and diabetic retinal diseases. Ophthalmologists and retinal specialists use Ellex photocoagulators to cauterize and remove the unwanted leaky blood vessels that disturb retinal function, as well as to repair retinal tears and detachments caused by those same vessels. Specific models include the Integre Duo, Integre and Solitaire. 
  
  Innovative Imaging – Ophthalmologists use our high-resolution ultrasound imaging devices to visualize anatomy and structures below the surface of the retina, which is often where unwanted blood vessels and other problems originate. Ellex offers the premium ophthalmic ultrasound, the Ellex Eye Cubed, to image complex ocular structures.

• Glaucoma is a disease that affects the optic nerve, and is the leading cause of blindness in the developed world. Glaucoma patients often have no symptoms in the early stages of the disease and begin to develop blind spots once there is irreversible damage to the optic nerve. If the entire nerve is destroyed, blindness results – but loss of vision can be avoided if glaucoma is detected and treated early.
  
  

  SLT Photoregeneration – Ellex is the global leader in lasers to treat glaucoma. Ophthalmologists use our Selective Laser Trabeculoplasty (SLT) lasers to deliver short pulses of low-energy light that trigger the body’s natural healing mechanisms. This process reduces intraocular pressure (IOP) associated with glaucoma in order to preserve optic nerve function. SLT does not harm the eye and has no side effects, which allows earlier treatment.